Dr. Beverly Moy's Avatar

Dr. Beverly Moy

@beverlymoy.bsky.social

Medical Oncologist, Clinical Director of Breast Oncology, Vice Chief of Quality, Safety, and DEI at Mass General Cancer Center. Professor at Harvard Medical School. Views my own.

133 Followers  |  76 Following  |  2 Posts  |  Joined: 18.11.2024  |  1.4328

Latest posts by beverlymoy.bsky.social on Bluesky

Preview
Gastrointestinal Cancer Gastrointestinal Cancer

@ascocancer.bsky.social #ASCOGuidelines out today "Systemic Therapy for Stage I-III Anal Carcinoma" with guidance about radiosensitization, dose/scheduling options, and much more. @vanmorrismd.bsky.social @cathyengmd.bsky.social Read at society.asco.org/practice-pat...

16.12.2024 23:48 — 👍 5    🔁 2    💬 0    📌 0
Post image

No matter what's happening in the world, it's so great to know that you have the very best colleagues in the world at Mass General Brigham Breast Center. @ethicsdoctorp.bsky.social and many others. So thankful for them this Thanksgiving.

26.11.2024 02:46 — 👍 7    🔁 1    💬 0    📌 0
Visual abstract for Systemic Therapy for SCLC Rapid Guideline Update: 2.4. Patients with LS-SCLC who have completed concurrent chemoradiotherapy and do not have disease progression should be offered consolidation immunotherapy (durvalumab) for up to 2 years if there are no contraindications to immunotherapy. (Evidence quality: Moderate; Strength of recommendation: Strong) 5.3.1. Patients with LS-SCLC and ECOG PS 3-4 due to SCLC who have been treated with concurrent or sequential chemotherapy and radiotherapy may be offered consolidation immunotherapy (durvalumab) for up to 2 years if there are no contraindications to immunotherapy and there is improvement in PS. (Evidence quality: Low; Strength of recommendation: Conditional) 4.1. In patients with relapsed SCLC with a chemotherapy-free interval of less than 90 days, single-agent systemic therapy may be offered. Preferred agents are topotecan, lurbinectedin or tarlatamab. (Evidence quality: Moderate; Strength of recommendation: Strong) 4.2. In patients with relapsed SCLC with a chemotherapy-free interval of at least 90 days, re-challenge with a platinum-based regimen or single-agent chemotherapy (preferred agents are topotecan, lurbinectedin or tarlatamab) may be offered. (Evidence quality: Moderate; Strength of recommendation: Strong) Kalemkerian et al J Clin Oncol 2024 asco.org/thoracic-cancer-guidelines

Visual abstract for Systemic Therapy for SCLC Rapid Guideline Update: 2.4. Patients with LS-SCLC who have completed concurrent chemoradiotherapy and do not have disease progression should be offered consolidation immunotherapy (durvalumab) for up to 2 years if there are no contraindications to immunotherapy. (Evidence quality: Moderate; Strength of recommendation: Strong) 5.3.1. Patients with LS-SCLC and ECOG PS 3-4 due to SCLC who have been treated with concurrent or sequential chemotherapy and radiotherapy may be offered consolidation immunotherapy (durvalumab) for up to 2 years if there are no contraindications to immunotherapy and there is improvement in PS. (Evidence quality: Low; Strength of recommendation: Conditional) 4.1. In patients with relapsed SCLC with a chemotherapy-free interval of less than 90 days, single-agent systemic therapy may be offered. Preferred agents are topotecan, lurbinectedin or tarlatamab. (Evidence quality: Moderate; Strength of recommendation: Strong) 4.2. In patients with relapsed SCLC with a chemotherapy-free interval of at least 90 days, re-challenge with a platinum-based regimen or single-agent chemotherapy (preferred agents are topotecan, lurbinectedin or tarlatamab) may be offered. (Evidence quality: Moderate; Strength of recommendation: Strong) Kalemkerian et al J Clin Oncol 2024 asco.org/thoracic-cancer-guidelines

New rapid recommendation update on systemic therapy for small-cell lung cancer from ASCO just published: ascopubs.org/doi/full/10.... #ASCOguidelines #MedSky #OncSky #LCSM

20.11.2024 21:39 — 👍 16    🔁 8    💬 2    📌 0

@beverlymoy is following 20 prominent accounts